These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29463535)

  • 1. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
    Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.
    Hattori SI; Hayashi H; Bulut H; Rao KV; Nyalapatla PR; Hasegawa K; Aoki M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
    Ide K; Aoki M; Amano M; Koh Y; Yedidi RS; Das D; Leschenko S; Chapsal B; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1717-27. PubMed ID: 21282450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.
    Amano M; Miguel Salcedo-Gómez P; Yedidi RS; Delino NS; Nakata H; Venkateswara Rao K; Ghosh AK; Mitsuya H
    Sci Rep; 2017 Sep; 7(1):12235. PubMed ID: 28947797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
    Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Parham GL; Nyalapatla PR; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2015 May; 59(5):2625-35. PubMed ID: 25691652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance.
    Aoki M; Chang SB; Das D; Martyr C; Delino NS; Takamatsu Y; Ghosh AK; Mitsuya H
    Glob Health Med; 2019 Oct; 1(1):36-48. PubMed ID: 33330753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
    Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors
    Amano M; Yedidi RS; Salcedo-Gómez PM; Hayashi H; Hasegawa K; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0171521. PubMed ID: 34978889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.
    Koh Y; Amano M; Towata T; Danish M; Leshchenko-Yashchuk S; Das D; Nakayama M; Tojo Y; Ghosh AK; Mitsuya H
    J Virol; 2010 Nov; 84(22):11961-9. PubMed ID: 20810732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
    J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
    Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.